Born from Institut Curie's incubation program, Mnemo Therapeutics is a biotech company which uses epigenetics to develop new approaches in immunotherapy. Its approach to tackling difficult-to-treat tumours is rooted in its ground-breaking immuno-epigenetic knowledge and expertise combined with the latest developments in T cell engineering.
Year of creation: 2019
Line of business: Biotechnology
Institut Curie: Incubator, institutional co-founder and R&D partner
Mnemo Therapeutics leverages epigenetic reprogramming of immune cells to improve their persistence and ability to identify tumor cells.
The company is focused on improving three key features of CAR-T cell therapy:
- Enhancing the persistence and fitness of T cells
- Identifying and targeting more accessible and specific cancer antigen targets
- Bringing allogeneic treatments to patients.